New therapeutic choices for infections caused by methicillin-resistant Staphylococcus aureus

Clinical Microbiology and Infection

Volumn 15, Issue SUPPL. 7, 2009, Pages 44-52

  Bouza, E ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Ceftarole; Ceftobiprole; Daptomycin; Gram positives; Linzolid; MRSA; Review; Tigecycline; Treatment; Vanomycin

Indexed keywords

AMPICILLIN PLUS DICLOXACILLIN; CEFTAROLINE; CEFTOBIPROLE; CEFTRIAXONE; CHLORAMPHENICOL; COTRIMOXAZOLE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DOXYCYCLINE; FOSFOMYCIN; FUSIDIC ACID; ICLAPRIM; LINEZOLID; ORITAVANCIN; PENICILLIN G; PLACEBO; RIFAMPICIN; TEFIBAZUMAB; TELAVANCIN; TIGECYCLINE; TOMOPENEM; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; ARTHRALGIA; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERIAL STRAIN; BACTERIUM ISOLATE; BONE INFECTION; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CATHETER INFECTION; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DIARRHEA; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; ENDOCARDITIS; ENDOPHTHALMITIS; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HOSPITAL INFECTION; HUMAN; HYPERBILIRUBINEMIA; INFECTIOUS ARTHRITIS; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; JAUNDICE; LACTIC ACIDOSIS; LIVER TOXICITY; MENINGITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; OPTIC NERVE DISEASE; OSTEOMYELITIS; OTOTOXICITY; PARTIAL THROMBOPLASTIN TIME; PERIPHERAL NEUROPATHY; PHLEBITIS; PNEUMONIA; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PROTHROMBIN TIME; QT PROLONGATION; RESPIRATORY TRACT INFECTION; REVIEW; SEPTICEMIA; SIDE EFFECT; SINGLE DRUG DOSE; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCAL BACTEREMIA; THROMBOCYTOPENIA; TISSUE DISTRIBUTION; VASOSPASM; VENTILATOR ASSOCIATED PNEUMONIA; VOMITING;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; POSIBACTERIA;

EID: 71649103462     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2009.03091.x     Document Type: Review

References (315)

1. Lodise TP, Graves J, Evans A. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008, 52:3315-3320.
2. Mohr JF, Murray BE. Point: vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2007, 44:1536-1542.
3. Kollef MH. Limitations of vancomycin in the management of resistant staphylococcal infections. Clin Infect Dis 2007, 45(suppl 3):S191-S195.
4. Howden BP, Johnson PD, Ward PB, Stinear TP, Davies JK. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2006, 50:3039-3047.
5. Howden BP, Johnson PD, Charles PG, Grayson ML. Failure of vancomycin for treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2004, 39:1544.
6. Cunha BA. Vancomycin revisited: a reappraisal of clinical use. Crit Care Clin 2008, 24:393-420.
7. Levine DP. Vancomycin: understanding its past and preserving its future. South Med J 2008, 101:284-291.
8. Fortun J, Navas E, Martinez-Beltran J. Short-course therapy for right-side endocarditis due to Staphylococcus aureus in drug abusers: cloxacillin versus glycopeptides in combination with gentamicin. Clin Infect Dis 2001, 33:120-125.
9. Sievert DM, Rudrik JT, Patel JB, McDonald LC, Wilkins MJ, Hageman JC. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis 2008, 46:668-674.
10. Tenover FC. Vancomycin-resistant Staphylococcus aureus: a perfect but geographically limited storm? Clin Infect Dis 2008, 46:675-677.
11. Tiwari HK, Sen MR. Emergence of vancomycin resistant Staphylococcus aureus (VRSA) from a tertiary care hospital from northern part of India. BMC Infect Dis 2006, 6:156.
12. Hiramatsu K, Aritaka N, Hanaki H. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997, 350:1670-1673.
13. Garnier F, Chainier D, Walsh T. A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital. J Antimicrob Chemother 2006, 57:146-149.
14. Sakoulas G, Moellering RC. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains. Clin Infect Dis 2008, 46(suppl 5):S360-S367.
15. Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother 2007, 60:788-794.
16. Moise PA, Sakoulas G, Forrest A, Schentag JJ. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2007, 51:2582-2586.
17. Wang G, Hindler JF, Ward KW, Bruckner DA. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 2006, 44:3883-3886.
18. Fridkin SK, Hageman J, McDougal LK. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin Infect Dis 2003, 36:429-439.
19. Holmes RL, Jorgensen JH. Inhibitory activities of 11 antimicrobial agents and bactericidal activities of vancomycin and daptomycin against invasive methicillin-resistant Staphylococcus aureus isolates obtained from 1999 through 2006. Antimicrob Agents Chemother 2008, 52:757-760.
20. Alos JI, Garcia-Canas A, Garcia-Hierro P, Rodriguez-Salvanes F. Vancomycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage. J Antimicrob Chemother 2008, 62:773-775.
21. Tenover FC, Moellering RC. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007, 44:1208-1215.
22. Soriano A, Marco F, Martinez JA. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008, 46:193-200.
23. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006, 166:2138-2144.
24. Schaad HJ, Chuard C, Vaudaux P, Waldvogel FA, Lew DP. Teicoplanin alone or combined with rifampin compared with vancomycin for prophylaxis and treatment of experimental foreign body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1994, 38:1703-1710.
25. Palmer SM, Rybak MJ. Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clots. Antimicrob Agents Chemother 1996, 40:701-705.
26. Watanakunakorn C, Guerriero JC. Interaction between vancomycin and rifampin against Staphylococcus aureus. Antimicrob Agents Chemother 1981, 19:1089-1091.
27. Kang-Birken SL. Comparative in vitro activity of vancomycin and levofloxacin in combination with rifampin against planktonic versus sessile cells of Staphylococcus epidermidis. Pharmacotherapy 2000, 20:673-678.
28. Dworkin R, Modin G, Kunz S, Rich R, Zak O, Sande M. Comparative efficacies of ciprofloxacin, pefloxacin, and vancomycin in combination with rifampin in a rat model of methicillin-resistant Staphylococcus aureus chronic osteomyelitis. Antimicrob Agents Chemother 1990, 34:1014-1016.
29. Henry NK, Rouse MS, Whitesell AL, McConnell ME, Wilson WR. Treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis with ciprofloxacin or vancomycin alone or in combination with rifampin. Am J Med 1987, 82:73-75.
30. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991, 115:674-680.
31. Bayer AS, Lam K. Efficacy of vancomycin plus rifampin in experimental aortic-valve endocarditis due to methicillin-resistant Staphylococcus aureus: in vitro-in vivo correlations. J Infect Dis 1985, 151:157-165.
32. Riedel DJ, Weekes E, Forrest GN. Addition of rifampin to standard therapy for treatment of native valve infective endocarditis caused by Staphylococcus aureus. Antimicrob Agents Chemother 2008, 52:2463-2467.
33. Perlroth J, Kuo M, Tan J, Bayer AS, Miller LG. Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature. Arch Intern Med 2008, 168:805-819.
34. Mulazimoglu L, Drenning SD, Muder RR. Vancomycin-gentamicin synergism revisited: effect of gentamicin susceptibility of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1996, 40:1534-1535.
35. Tsuji BT, Rybak MJ. Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2005, 49:2735-2745.
36. LaPlante KL, Rybak MJ. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2004, 48:4665-4672.
37. Houlihan HH, Mercier RC, Rybak MJ. Pharmacodynamics of vancomycin alone and in combination with gentamicin at various dosing intervals against methicillin-resistant Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model. Antimicrob Agents Chemother 1997, 41:2497-2501.
38. Perdikaris G, Giamarellou H, Pefanis A, Donta I, Karayiannakos P. Vancomycin or vancomycin plus netilmicin for methicillin- and gentamicin-resistant Staphylococcus aureus aortic valve experimental endocarditis. Antimicrob Agents Chemother 1995, 39:2289-2294.
39. Fauconneau B, Favreliere S, Pariat C. Nephrotoxicity of gentamicin and vancomycin given alone and in combination as determined by enzymuria and cortical antibiotic levels in rats. Ren Fail 1997, 19:15-22.
40. Goetz MB, Sayers J. Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination. J Antimicrob Chemother 1993, 32:325-334.
41. Fauconneau B, De Lemos E, Pariat C, Bouquet S, Courtois P, Piriou A. Chrononephrotoxicity in rat of a vancomycin and gentamicin combination. Pharmacol Toxicol 1992, 71:31-36.
42. Rybak MJ, Albrecht LM, Boike SC, Chandrasekar PH. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 1990, 25:679-687.
43. Swinney VR, Rudd CC. Nephrotoxicity of vancomycin-gentamicin therapy in pediatric patients. J Pediatr 1987, 110:497-498.
44. Dean RP, Wagner DJ, Tolpin MD. Vancomycin/aminoglycoside nephrotoxicity. J Pediatr 1985, 106:861-862.
45. Abrams B, Sklaver A, Hoffman T, Greenman R. Single or combination therapy of staphylococcal endocarditis in intravenous drug abusers. Ann Intern Med 1979, 90:789-791.
46. Korzeniowski O, Sande MA. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: a prospective study. Ann Intern Med 1982, 97:496-503.
47. Burkhardt O, Pletz MW, Mertgen CP, Welte T. Linezolid-the first oxazolidinone in the treatment of nosocomial MRSA pneumonia. Recent Patents Anti-Infect Drug Disc 2007, 2:123-130.
48. Wilcox MH. Update on linezolid: the first oxazolidinone antibiotic. Expert Opin Pharmacother 2005, 6:2315-2326.
49. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002, 34:1481-1490.
50. Stevens DL, Dotter B, Madaras-Kelly K. A review of linezolid: the first oxazolidinone antibiotic. Expert Rev Anti Infect Ther 2004, 2:51-59.
51. Hentschke M, Saager B, Horstkotte MA. Emergence of linezolid resistance in a methicillin resistant Staphylococcus aureus strain. Infection 2008, 36:85-87.
52. Meka VG, Pillai SK, Sakoulas G. Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA. J Infect Dis 2004, 190:311-317.
53. Tsiodras S, Gold HS, Sakoulas G. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001, 358:207-208.
54. Arias CA, Vallejo M, Reyes J. Clinical and microbiological aspects of linezolid resistance mediated by the cfr gene encoding a 23S rRNA methyltransferase. J Clin Microbiol 2008, 46:892-896.
55. Toh SM, Xiong L, Arias CA. Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Mol Microbiol 2007, 64:1506-1514.
56. Kola A, Kirschner P, Gohrbandt B. An infection with linezolid-resistant S. aureus in a patient with left ventricular assist system. Scand J Infect Dis 2007, 39:463-465.
57. Zhu W, Tenover FC, Limor J. Use of pyrosequencing to identify point mutations in domain V of 23S rRNA genes of linezolid-resistant Staphylococcus aureus and Staphylococcus epidermidis. Eur J Clin Microbiol Infect Dis 2007, 26:161-165.
58. Roberts SM, Freeman AF, Harrington SM, Holland SM, Murray PR, Zelazny AM. Linezolid-resistant Staphylococcus aureus in two pediatric patients receiving low-dose linezolid therapy. Pediatr Infect Dis J 2006, 25:562-564.
59. Gales AC, Sader HS, Andrade SS, Lutz L, Machado A, Barth AL. Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis. Int J Antimicrob Agents 2006, 27:300-302.
60. Peeters MJ, Sarria JC. Clinical characteristics of linezolid-resistant Staphylococcus aureus infections. Am J Med Sci 2005, 330:102-104.
61. Meka VG, Gold HS, Cooke A. Reversion to susceptibility in a linezolid-resistant clinical isolate of Staphylococcus aureus. J Antimicrob Chemother 2004, 54:818-820.
62. Dresser LD, Rybak MJ. The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials. Pharmacotherapy 1998, 18:456-462.
63. Tsuji Y, Hiraki Y, Mizoguchi A. Pharmacokinetics of repeated dosing of linezolid in a hemodialysis patient with chronic renal failure. J Infect Chemother 2008, 14:156-160.
64. Stolle LB, Plock N, Joukhadar C. Pharmacokinetics of linezolid in bone tissue investigated by in vivo microdialysis. Scand J Infect Dis 2008, 40:24-29.
65. Velissariou IM. Linezolid in children: recent patents and advances. Recent Patents Anti-Infect Drug Disc 2007, 2:73-77.
66. Stein GE, Schooley S, Peloquin CA, Missavage A, Havlichek DH. Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infections. J Antimicrob Chemother 2007, 60:819-823.
67. Mauro LS, Peloquin CA, Schmude K, Assaly R, Malhotra D. Clearance of linezolid via continuous venovenous hemodiafiltration. Am J Kidney Dis 2006, 47:e83-e86.
68. Cuzzolin L, Fanos V. Linezolid: a new antibiotic for newborns and children? J Chemother 2006, 18:573-581.
69. Fiaccadori E, Maggiore U, Rotelli C. Does haemodialysis significantly affect serum linezolid concentrations in critically ill patients with renal failure? A pilot investigation. Nephrol Dial Transplant 2006, 21:1402-1406.
70. Meyer B, Kornek GV, Nikfardjam M. Multiple-dose pharmacokinetics of linezolid during continuous venovenous haemofiltration. J Antimicrob Chemother 2005, 56:172-179.
71. Fiaccadori E, Maggiore U, Rotelli C. Removal of linezolid by conventional intermittent hemodialysis, sustained low-efficiency dialysis, or continuous venovenous hemofiltration in patients with acute renal failure. Crit Care Med 2004, 32:2437-2442.
72. Clemett D, Markham A. Linezolid. Drugs 2000, 59:815-827.
73. Norrby R. Linezolid-a review of the first oxazolidinone. Expert Opin Pharmacother 2001, 2:293-302.
74. Hau T. Efficacy and safety of linezolid in the treatment of skin and soft tissue infections. Eur J Clin Microbiol Infect Dis 2002, 21:491-498.
75. French G. Safety and tolerability of linezolid. J Antimicrob Chemother 2003, 51(suppl 2):ii45-ii53.
76. Meissner HC, Townsend T, Wenman W. Hematologic effects of linezolid in young children. Pediatr Infect Dis J 2003, 22(suppl 9):S186-S192.
77. Saiman L, Goldfarb J, Kaplan SA. Safety and tolerability of linezolid in children. Pediatr Infect Dis J 2003, 22(suppl 9):S193-S200.
78. Ferry T, Ponceau B, Simon M. Possibly linezolid-induced peripheral and central neurotoxicity: report of four cases. Infection 2005, 33:151-154.
79. Shorr AF, Kunkel MJ, Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother 2005, 56:923-929.
80. Tsaganos T, Skiadas I, Koutoukas P. Efficacy and pharmacodynamics of linezolid, alone and in combination with rifampicin, in an experimental model of methicillin-resistant Staphylococcus aureus endocarditis. J Antimicrob Chemother 2008, 62:381-383.
81. Munoz P, Rodriguez-Creixems M, Moreno M, Marin M, Ramallo V, Bouza E. Linezolid therapy for infective endocarditis. Clin Microbiol Infect 2007, 13:211-215.
82. Wareham DW, Abbas H, Karcher AM, Das SS. Treatment of prosthetic valve infective endocarditis due to multi-resistant Gram-positive bacteria with linezolid. J Infect 2006, 52:300-304.
83. Rubinstein E, Cammarata S, Oliphant T, Wunderink R. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001, 32:402-412.
84. Grudinina SA, Zubkov MM, Krotova LA. Comparison of linezolid and vancomycin in nosocomial pneumonia: results of the multicenter double-blind study. Antibiot Khimioter 2002, 47:12-17.
85. Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 2003, 25:980-992.
86. Kollef MH, Rello J, Cammarata SK, Croos-Dabrera RV, Wunderink RG. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 2004, 30:388-394.
87. San Pedro GS, Cammarata SK, Oliphant TH, Todisco T. Linezolid versus ceftriaxone/cefpodoxime in patients hospitalized for the treatment of Streptococcus pneumoniae pneumonia. Scand J Infect Dis 2002, 34:720-728.
88. Kaplan SL, Patterson L, Edwards KM. Linezolid for the treatment of community-acquired pneumonia in hospitalized children. Linezolid Pediatric Pneumonia Study Group. Pediatr Infect Dis J 2001, 20:488-494.
89. Stevens DL, Smith LG, Bruss JB. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2000, 44:3408-3413.
90. Li JZ, Willke RJ, Rittenhouse BE, Rybak MJ. Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial. Surg Infect (Larchmt) 2003, 4:57-70.
91. Itani KM, Weigelt J, Li JZ, Duttagupta S. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 2005, 26:442-448.
92. Wilcox MH, Tack KJ, Bouza E. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis 2009, 48:203-212.
93. Falagas ME, Siempos II, Papagelopoulos PJ, Vardakas KZ. Linezolid for the treatment of adults with bone and joint infections. Int J Antimicrob Agents 2007, 29:233-239.
94. Kutscha-Lissberg F, Hebler U, Muhr G, Koller M. Linezolid penetration into bone and joint tissues infected with methicillin-resistant staphylococci. Antimicrob Agents Chemother 2003, 47:3964-3966.
95. Lovering AM, Zhang J, Bannister GC. Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J Antimicrob Chemother 2002, 50:73-77.
96. Vercillo M, Patzakis MJ, Holtom P, Zalavras CG. Linezolid in the treatment of implant-related chronic osteomyelitis. Clin Orthop Relat Res 2007, 461:40-43.
97. Broder KW, Moise PA, Schultz RO, Forrest A, Schentag JJ. Clinical experience with linezolid in conjunction with wound coverage techniques for skin and soft-tissue infections and postoperative osteomyelitis. Ann Plast Surg 2004, 52:385-390.
98. Pasticci MB, Altissimi M, Azzara A. Treatment of post-traumatic hand Staphylococcus aureus osteomyelitis with oral linezolid. J Chemother 2006, 18:425-429.
99. Senneville E, Legout L, Valette M. Effectiveness and tolerability of prolonged linezolid treatment for chronic osteomyelitis: a retrospective study. Clin Ther 2006, 28:1155-1163.
100. Aneziokoro CO, Cannon JP, Pachucki CT, Lentino JR. The effectiveness and safety of oral linezolid for the primary and secondary treatment of osteomyelitis. J Chemother 2005, 17:643-650.
101. Rayner CR, Baddour LM, Birmingham MC, Norden C, Meagher AK, Schentag JJ. Linezolid in the treatment of osteomyelitis: results of compassionate use experience. Infection 2004, 32:8-14.
102. Patel R, Piper KE, Rouse MS, Steckelberg JM. Linezolid therapy of Staphylococcus aureus experimental osteomyelitis. Antimicrob Agents Chemother 2000, 44:3438-3440.
103. Bassetti M, Vitale F, Melica G. Linezolid in the treatment of Gram-positive prosthetic joint infections. J Antimicrob Chemother 2005, 55:387-390.
104. Oussedik SI, Haddad FS. The use of linezolid in the treatment of infected total joint arthroplasty. J Arthroplasty 2008, 23:273-278.
105. You JH, Lee GC, So RK, Cheung KW, Hui M. Linezolid versus vancomycin for prosthetic joint infections: a cost analysis. Infection 2007, 35:265-270.
106. Tattevin P, Arvieux C, Michelet C. What is the place of teicoplanin and linezolid in the treatment of prosthetic joint infections? Clin Microbiol Infect 2006, 12:1241-1242.
107. Falagas ME, Manta KG, Ntziora F, Vardakas KZ. Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J Antimicrob Chemother 2006, 58:273-280.
108. Cunha BA, Krol V, Kodali V. Methicillin-resistant Staphylococcus aureus (MRSA) mitral valve acute bacterial endocarditis (ABE) in a patient with Job's syndrome (hyperimmunoglobulin E syndrome) successfully treated with linezolid and high-dose daptomycin. Heart Lung 2008, 37:72-75.
109. Kallweit U, Harzheim M, Marklein G, Welt T, Pohlau D. Successful treatment of methicillin-resistant Staphylococcus aureus meningitis using linezolid without removal of intrathecal infusion pump. Case report. J Neurosurg 2007, 107:651-653.
110. Kessler AT, Kourtis AP. Treatment of meningitis caused by methicillin-resistant Staphylococcus aureus with linezolid. Infection 2007, 35:271-274.
111. Nagashima G, Okamoto N, Okuda M. Effect of linezolid against postneurosurgical meningitis caused by methicillin-resistant Staphylococcus epidermidis: case report. J Infect Chemother. 2008, 14:147-150.
112. Mizell KN, Carter JE. Vancomycin-resistant Enterococcus faecium meningitis successfully treated with linezolid. South Med J 2008, 101:569-570.
113. Dinleyici EC, Yarar C, Dinleyici M, Yakut A. Successful treatment with linezolid of meningitis complicated with subdural empyema in a 6-month-old boy. J Trop Pediatr 2007, 53:431-433.
114. Ramirez P, Sahuquillo JM, Cortes C, Kot P, Bonastre JM. Linezolid as rescue therapy for pneumococcal meningitis. Intensive Care Med 2007, 33:924-925.
115. Kruse AJ, Peerdeman SM, Bet PM, Debets-Ossenkopp YJ. Successful treatment with linezolid and rifampicin of meningitis due to methicillin-resistant Staphylococcus epidermidis refractory to vancomycin treatment. Eur J Clin Microbiol Infect Dis 2006, 25:135-137.
116. Steinmetz MP, Vogelbaum MA, De Georgia MA, Andrefsky JC, Isada C. Successful treatment of vancomycin-resistant enterococcus meningitis with linezolid: case report and review of the literature. Crit Care Med 2001, 29:2383-2385.
117. Hachem R, Afif C, Gokaslan Z, Raad I. Successful treatment of vancomycin-resistant Enterococcus meningitis with linezolid. Eur J Clin Microbiol Infect Dis 2001, 20:432-434.
118. Shaikh ZH, Peloquin CA, Ericsson CD. Successful treatment of vancomycin-resistant Enterococcus faecium meningitis with linezolid: case report and literature review. Scand J Infect Dis 2001, 33:375-379.
119. Amod F, Moodley I, Peer AK. Ventriculitis due to a hetero strain of vancomycin intermediate Staphylococcus aureus (hVISA): successful treatment with linezolid in combination with intraventricular vancomycin. J Infect 2005, 50:252-257.
120. Beer R, Engelhardt KW, Pfausler B. Pharmacokinetics of intravenous linezolid in cerebrospinal fluid and plasma in neurointensive care patients with staphylococcal ventriculitis associated with external ventricular drains. Antimicrob Agents Chemother 2007, 51:379-382.
121. Boak LM, Li J, Spelman D, du Cros P, Nation RL, Rayner CR. Successful treatment and cerebrospinal fluid penetration of oral linezolid in a patient with coagulase-negative Staphylococcus ventriculitis. Ann Pharmacother 2006, 40:1451-1455.
122. Graham PL, Ampofo K, Saiman L. Linezolid treatment of vancomycin-resistant Enterococcus faecium ventriculitis. Pediatr Infect Dis J 2002, 21:798-800.
123. Salin F, Vianello F, Manara R. Linezolid in the treatment of brain abscess due to Peptostreptococcus. Scand J Infect Dis 2006, 38:203-205.
124. Proctor RA. Role of folate antagonists in the treatment of methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2008, 46:584-593.
125. Grim SA, Rapp RP, Martin CA, Evans ME. Trimethoprim-sulfamethoxazole as a viable treatment option for infections caused by methicillin-resistant Staphylococcus aureus. Pharmacotherapy 2005, 25:253-264.
126. Udo EE, Al-Sweih N, Mokaddas E. Antibacterial resistance and their genetic location in MRSA isolated in Kuwait hospitals, 1994-2004. BMC Infect Dis 2006, 6:168.
127. Bishara J, Pitlik S, Samra Z, Levy I, Paul M, Leibovici L. Co-trimoxazole-sensitive, methicillin-resistant Staphylococcus aureus, Israel, 1988-1997. Emerg Infect Dis 2003, 9:1168-1169.
128. Chen AE, Goldstein M, Carroll K, Song X, Perl TM, Siberry GK. Evolving epidemiology of pediatric Staphylococcus aureus cutaneous infections in a Baltimore hospital. Pediatr Emerg Care 2006, 22:717-723.
129. Cuevas O, Cercenadol E, José GM. Staphylococcus spp. en España: situación actual y evolución de la resistencia a antimicrobianos (1986-2006). Enferm Infecc Microbiol Clin 2008, 26:269-277. (in Spanish)
130. Cuevas O, Cercenado E, Vindel A. Evolution of the antimicrobial resistance of Staphylococcus spp. in Spain: five nationwide prevalence studies, 1986 to 2002. Antimicrob Agents Chemother 2004, 48:4240-4245.
131. de Gorgolas M, Aviles P, Verdejo C, Fernandez Guerrero ML. Treatment of experimental endocarditis due to methicillin-susceptible or methicillin-resistant Staphylococcus aureus with trimethoprim-sulfamethoxazole and antibiotics that inhibit cell wall synthesis. Antimicrob Agents Chemother 1995, 39:953-957.
132. Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med 1992, 117:390-398.
133. Cenizal MJ, Skiest D, Luber S. Prospective randomized trial of empiric therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2007, 51:2628-2630.
134. Walsh TJ, Standiford HC, Reboli AC. Randomized double-blinded trial of rifampin with either novobiocin or trimethoprim-sulfamethoxazole against methicillin-resistant Staphylococcus aureus colonization: prevention of antimicrobial resistance and effect of host factors on outcome. Antimicrob Agents Chemother 1993, 37:1334-1342.
135. Adra M, Lawrence K. Trimethoprim/sulfamethoxazole for treatment of severe Staphylococcus aureus infections. Ann Pharmacother 2004, 38:338-341.
136. Howden BP, Grayson ML. Dumb and dumber-the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus. Clin Infect Dis 2006, 42:394-400.
137. Anderson JD. Fusidic acid: new opportunities with an old antibiotic. Can Med Assoc J 1980, 122:765-769.
138. Fantin B, Leclercq R, Duval J, Carbon C. Fusidic acid alone or in combination with vancomycin for therapy of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1993, 37:2466-2469.
139. Collignon P, Turnidge J. Fusidic acid in vitro activity. Int J Antimicrob Agents 1999, 12(suppl 2):S45-S58.
140. Rennie RP. Susceptibility of Staphylococcus aureus to fusidic acid: Canadian data. J Cutan Med Surg 2006, 10:277-280.
141. Zinn CS, Westh H, Rosdahl VT. An international multicenter study of antimicrobial resistance and typing of hospital Staphylococcus aureus isolates from 21 laboratories in 19 countries or states. Microb Drug Resist 2004, 10:160-168.
142. Nielsen SL, Black FT. The effect of dicloxacillin and fusidic acid on the extracellular and intracellular killing of Staphylococcus aureus. J Antimicrob Chemother 1998, 42:221-226.
143. Drugeon HB, Caillon J, Juvin ME. In-vitro antibacterial activity of fusidic acid alone and in combination with other antibiotics against methicillin-sensitive and -resistant Staphylococcus aureus. J Antimicrob Chemother 1994, 34:899-907.
144. Foldes M, Munro R, Sorrell TC, Shanker S, Toohey M. In-vitro effects of vancomycin, rifampicin, and fusidic acid, alone and in combination, against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 1983, 11:21-26.
145. Kanellakopoulou K, Tselikos D, Giannitsioti E. Pharmacokinetics of fusidic acid and cefepime in heart tissues: implications for a role in surgical prophylaxis. J Chemother 2008, 20:468-471.
146. Turnidge J. Fusidic acid pharmacology, pharmacokinetics and pharmacodynamics. Int J Antimicrob Agents 1999, 12(suppl 2):S23-S34.
147. Spelman D. Fusidic acid in skin and soft tissue infections. Int J Antimicrob Agents 1999, 12(suppl 2):S59-S66.
148. Whitby M. Fusidic acid in the treatment of methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents 1999, 12(suppl 2):S67-S71.
149. Aboltins CA, Page MA, Buising KL. Treatment of staphylococcal prosthetic joint infections with debridement, prosthesis retention and oral rifampicin and fusidic acid. Clin Microbiol Infect 2007, 13:586-591.
150. Drancourt M, Stein A, Argenson JN, Roiron R, Groulier P, Raoult D. Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin. J Antimicrob Chemother 1997, 39:235-240.
151. Whitby M. Fusidic acid in septicaemia and endocarditis. Int J Antimicrob Agents 1999, 12(suppl 2):S17-S22.
152. Parras F, Guerrero MC, Bouza E. Comparative study of mupirocin and oral co-trimoxazole plus topical fusidic acid in eradication of nasal carriage of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1995, 39:175-179.
153. Dobie D, Gray J. Fusidic acid resistance in Staphylococcus aureus. Arch Dis Child 2004, 89:74-77.
154. Brown EM, Thomas P. Fusidic acid resistance in Staphylococcus aureus isolates. Lancet 2002, 359:803.
155. Turnidge J, Collignon P. Resistance to fusidic acid. Int J Antimicrob Agents 1999, 12(suppl 2):S35-S44.
156. Chang SC, Hsieh SM, Chen ML, Sheng WH, Chen YC. Oral fusidic acid fails to eradicate methicillin-resistant Staphylococcus aureus colonization and results in emergence of fusidic acid-resistant strains. Diagn Microbiol Infect Dis 2000, 36:131-136.
157. Christiansen K. Fusidic acid adverse drug reactions. Int J Antimicrob Agents 1999, 12(suppl 2):S3-S9.
158. Eykyn SJ. Staphylococcal bacteraemia and endocarditis and fusidic acid. J Antimicrob Chemother 1990, 25(suppl B):33-38.
159. Haddad M, Shabat S, Koren A, Stelman E, Zelikovski A. Fusidic acid induced jaundice. Eur J Clin Microbiol Infect Dis 1993, 12:725-726.
160. Hendlin D, Stapley EO, Jackson M. Phosphonomycin, a new antibiotic produced by strains of streptomyces. Science 1969, 166:122-123.
161. Gobernado M. Fosfomycin. Rev Esp Quimioter 2003, 16:15-40.
162. Nakazawa H, Kikuchi Y, Honda T, Isago T, Nozaki M. Enhancement of antimicrobial effects of various antibiotics against methicillin-resistant Staphylococcus aureus (MRSA) by combination with fosfomycin. J Infect Chemother 2003, 9:304-309.
163. Wongwanich S, Tishyadhigama P, Paisomboon S, Ohta T, Hayashi H. Epidemiological analysis of methicillin resistant Staphylococcus aureus in Thailand. Southeast Asian J Trop Med Public Health 2000, 31:72-76.
164. Mato R, Santos Sanches I, Venditti M. Spread of the multiresistant Iberian clone of methicillin-resistant Staphylococcus aureus (MRSA) to Italy and Scotland. Microb Drug Resist 1998, 4:107-112.
165. Graninger W, Leitha T, Havel M, Georgopoulos A. In vitro activity of fosfomycin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Infection 1984, 12:293-295.
166. Guenthner SH, Wenzel RP. In vitro activities of teichomycin, fusidic acid, flucloxacillin, fosfomycin, and vancomycin against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1984, 26:268-269.
167. Alvarez S, Jones M, Berk SL. In vitro activity of fosfomycin, alone and in combination, against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1985, 28:689-690.
168. Graninger W, Leitha T, Breyer S, Francesconi M, Lenz K, Georgopoulos A. Methicillin- and gentamicin-resistant Staphylococcus aureus: susceptibility to fosfomycin, cefamandole, N-formimidoyl-thienamycin, clindamycin, fusidic acid and vancomycin. Drugs Exp Clin Res 1985, 11:23-27.
169. Lau WY, Teoh-Chan CH, Fan ST, Lau KF. In vitro and in vivo study of fosfomycin in methicillin-resistant Staphylococcus aureus septicaemia. J Hyg (Lond) 1986, 96:419-423.
170. Grif K, Dierich MP, Pfaller K, Miglioli PA, Allerberger F. In vitro activity of fosfomycin in combination with various antistaphylococcal substances. J Antimicrob Chemother 2001, 48:209-217.
171. Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis 2008, 46:1069-1077.
172. Apisarnthanarak A, Mundy LM. Successful treatment of disseminated methicillin-resistant Staphylococcus aureus with fosfomycin, cefoperazone/sulbactam and rifampin followed by fusidic acid and rifampin. Int J Infect Dis 2007, 11:283-284.
173. Seto C, Ikeda A, Ohkawa M. A case report of urinary tract infection and meningitis caused by methicillin-resistant Staphylococcus aureus (MRSA) after transurethral resection of the prostate. Nippon Hinyokika Gakkai Zasshi 1999, 90:466-469.
174. Otsuka M, Sawahata T, Nakai T. Efficacy of combination therapy against MRSA in Ibaraki Prefecture. Jpn J Antibiot 1994, 47:781-789.
175. Ferrara A, Dos Santos C, Cimbro M, Gialdroni Grassi G. Effect of different combinations of sparfloxacin, oxacillin, and fosfomycin against methicillin-resistant staphylococci. Eur J Clin Microbiol Infect Dis 1997, 16:535-537.
176. Harada R, Miyamoto H, Sakao Y, Hamada T, Hata E. Combination therapy with arbekacin and fosfomycin against postoperative severe mixed-pneumonia of MRSA in primary lung cancer patients. Kyobu Geka 1995, 48:836-840.
177. Tanaka T, Iida-Tanaka K, Takahara J. Staggered intensive chemotherapy using arbekacin, fosfomycin and ceftazidime on polymicrobial infections involving MRSA. Jpn J Antibiot 1994, 47:790-797.
178. Kono K, Takeda S, Tatara I. Combined therapy with arbekacin and fosfomycin for methicillin-resistant Staphylococcus aureus infections. Jpn J Antibiot 1994, 47:798-803.
179. Hashimoto A, Ohtsubo T, Tomono K. Clinical effect of the combined therapy of arbekacin and imipenem/cilastatin against methicillin-resistant Staphylococcus aureus. Jpn J Antibiot 1994, 47:804-812.
180. Mendes RE, Sader HS, Deshpande L, Jones RN. Antimicrobial activity of tigecycline against community-acquired methicillin-resistant Staphylococcus aureus isolates recovered from North American medical centers. Diagn Microbiol Infect Dis 2008, 60:433-436.
181. Shittu AO, Lin J. Antimicrobial susceptibility patterns and characterization of clinical isolates of Staphylococcus aureus in KwaZulu-Natal province, South Africa. BMC Infect Dis 2006, 6:125.
182. Shanmuganathan VA, Armstrong M, Buller A, Tullo AB. External ocular infections due to methicillin-resistant Staphylococcus aureus (MRSA). Eye 2005, 19:284-291.
183. Hoban DJ, Biedenbach DJ, Mutnick AH, Jones RN. Pathogen of occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: results of the SENTRY Antimicrobial Surveillance Study (2000). Diagn Microbiol Infect Dis 2003, 45:279-285.
184. Oshiro T, Nagasawa Z, Hanaki H, Ikeda-Dantsuji Y, Nagayama A. The antagonistic effects of a combination of vancomycin and minocycline in Staphylococcus aureus with heterogeneous resistance to vancomycin. J Infect Chemother 2008, 14:15-22.
185. Bryson HM, Spencer CM. Quinupristin-dalfopristin. Drugs 1996, 52:406-415.
186. Cocito C, Di Giambattista M, Nyssen E, Vannuffel P. Inhibition of protein synthesis by streptogramins and related antibiotics. J Antimicrob Chemother 1997, 39(suppl A):7-13.
187. Norazah A, Lim VK, Rohani MY, Kamel AG. In-vitro activity of quinupristin/dalfopristin, levofloxacin and moxifloxacin against fusidic acid and rifampicin-resistant strains of methicillin-resistant Staphylococcus aureus (MRSA) from Malaysian hospitals. Med J Malaysia 2005, 60:411-415.
188. Millan L, Cerda P, Rubio MC. In vitro activity of telithromycin, quinupristin/dalfopristin, linezolid and comparator antimicrobial agents against Staphylococcus aureus clinical isolates. J Chemother 2004, 16:230-237.
189. Jorgen B, Merckoll P, Melby KK. Susceptibility to daptomycin, quinupristin-dalfopristin and linezolid and some other antibiotics in clinical isolates of methicillin resistant and methicillin sensitive S. aureus from the Oslo area. Scand J Infect Dis 2007, 39:1059-1062.
190. Smith PF, Booker BM, Ogundele AB, Kelchin P. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center. Diagn Microbiol Infect Dis 2005, 52:255-259.
191. Moellering RC, Linden PK, Reinhardt J, Blumberg EA, Bompart F, Talbot GH. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group. J Antimicrob Chemother 1999, 44:251-261.
192. Stamatakis MK, Richards JG. Interaction between quinupristin/dalfopristin and cyclosporine. Ann Pharmacother 1997, 31:576-578.
193. Nichols RL, Graham DR, Barriere SL. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group. J Antimicrob Chemother 1999, 44:263-273.
194. Eliopoulos GM. Antimicrobial agents for treatment of serious infections caused by resistant Staphylococcus aureus and enterococci. Eur J Clin Microbiol Infect Dis 2005, 24:826-831.
195. Hamel A, Caillon J, Jacqueline C, Batard E, Potel G. Efficacy of quinupristin/dalfopristin versus vancomycin, alone or in combination with rifampicin, against methicillin-resistant Staphylococcus aureus in a rabbit arthritis model. Int J Antimicrob Agents 2008, 31:158-160.
196. Maclayton DO, Hall RG. Pharmacologic treatment options for nosocomial pneumonia involving methicillin-resistant Staphylococcus aureus. Ann Pharmacother 2007, 41:235-244.
197. Weis F, Beiras-Fernandez A, Schelling G. Daptomycin, a lipopeptide antibiotic in clinical practice. Curr Opin Investig Drugs 2008, 9:879-884.
198. Sauermann R, Rothenburger M, Graninger W, Joukhadar C. Daptomycin: a review 4 years after first approval. Pharmacology 2008, 81:79-91.
199. Murthy MH, Olson ME, Wickert RW, Fey PD, Jalali Z. Daptomycin non-susceptible meticillin-resistant Staphylococcus aureus USA 300 isolate. J Med Microbiol 2008, 57:1036-1038.
200. Enoch DA, Bygott JM, Daly ML, Karas JA. Daptomycin. J Infect 2007, 55:205-213.
201. Ehlert F, Neu HC. In vitro activity of LY146032 (daptomycin), a new peptolide. Eur J Clin Microbiol 1987, 6:84-90.
202. Machka K, Braveny I. Comparative in vitro activity of LY146032 (daptomycin) against gram-positive cocci. Eur J Clin Microbiol 1987, 6:96-99.
203. Blenkharn JI, Darrell JH. Comparative in vitro activity of daptomycin (LY146032) and vancomycin against gram-positive cocci determined using a pharmacokinetic model. Eur J Clin Microbiol Infect Dis 1989, 8:734-737.
204. Cha R, Rybak MJ. Daptomycin against multiple drug-resistant staphylococcus and enterococcus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Diagn Microbiol Infect Dis 2003, 47:539-546.
205. Laganas V, Alder J, Silverman JA. In vitro bactericidal activities of daptomycin against Staphylococcus aureus and Enterococcus faecalis are not mediated by inhibition of lipoteichoic acid biosynthesis. Antimicrob Agents Chemother 2003, 47:2682-2684.
206. Fluit AC, Schmitz FJ, Verhoef J, Milatovic D. Daptomycin in vitro susceptibility in European Gram-positive clinical isolates. Int J Antimicrob Agents 2004, 24:59-66.
207. Sader HS, Fritsche TR, Streit JM, Jones RN. Daptomycin in vitro activity tested against Gram-positive strains collected from European and Latin American medical centers in 2003. J Chemother 2005, 17:477-483.
208. Pfaller MA, Sader HS, Jones RN. Evaluation of the in vitro activity of daptomycin against 19615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002-2005). Diagn Microbiol Infect Dis 2007, 57:459-465.
209. Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother 2003, 47:2538-2544.
210. Nau R, Eiffert H. Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis. Clin Microbiol Rev 2002, 15:95-110.
211. Scheld W, Dacey R, Winn H, Welsh J, Jane J, Sande M. Cerebrospinal fluid outflow resistance in rabbits with experimental meningitis: alterations with penicillin and methylprednisolone. J Clin Invest 1980, 66:243-253.
212. Burkhardt O, Joukhadar C, Traunmuller F, Hadem J, Welte T, Kielstein JT. Elimination of daptomycin in a patient with acute renal failure undergoing extended daily dialysis. J Antimicrob Chemother 2008, 61:224-225.
213. Churchwell MD, Pasko DA, Mueller BA. Daptomycin clearance during modeled continuous renal replacement therapy. Blood Purif 2006, 24:548-554.
214. Dvorchik B, Arbeit RD, Chung J, Liu S, Knebel W, Kastrissios H. Population pharmacokinetics of daptomycin. Antimicrob Agents Chemother 2004, 48:2799-2807.
215. Lipsky BA, Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J Antimicrob Chemother 2005, 55:240-245.
216. Johnson A. Daptomycin in the treatment of skin, soft-tissue and invasive infections due to Gram-positive bacteria. Future Microbiol 2006, 1:255-265.
217. Kern WV. Daptomycin: first in a new class of antibiotics for complicated skin and soft-tissue infections. Int J Clin Pract 2006, 60:370-378.
218. Martone WJ, Lamp KC. Efficacy of daptomycin in complicated skin and skin-structure infections due to methicillin-sensitive and -resistant Staphylococcus aureus: results from the CORE Registry. Curr Med Res Opin 2006, 22:2337-2343.
219. Davis SL, McKinnon PS, Hall LM. Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes. Pharmacotherapy 2007, 27:1611-1618.
220. Hair PI, Keam SJ. Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia. Drugs 2007, 67:1483-1512.
221. Owens RC, Lamp KC, Friedrich LV, Russo R. Postmarketing clinical experience in patients with skin and skin-structure infections treated with daptomycin. Am J Med 2007, 120(suppl 1):S6-S12.
222. Fowler VG, Boucher HW, Corey GR. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006, 355:653-665.
223. Burns CA. Long-term use of daptomycin for MRSA osteomyelitis and joint infection. Scand J Infect Dis 2008, 40:183-186.
224. Lamp KC, Friedrich LV, Mendez-Vigo L, Russo R. Clinical experience with daptomycin for the treatment of patients with osteomyelitis. Am J Med 2007, 120(suppl 1):S13-S20.
225. Rouse MS, Piper KE, Jacobson M, Jacofsky DJ, Steckelberg JM, Patel R. Daptomycin treatment of Staphylococcus aureus experimental chronic osteomyelitis. J Antimicrob Chemother 2006, 57:301-305.
226. Mader JT, Adams K. Comparative evaluation of daptomycin (LY146032) and vancomycin in the treatment of experimental methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits. Antimicrob Agents Chemother 1989, 33:689-692.
227. Vikram HR, Havill NL, Koeth LM, Boyce JM. Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin. J Clin Microbiol 2005, 43:5384-5387.
228. Luu QN, Buxton TB, Nelson DR, Rissing JP. Treatment of chronic experimental Staphylococcus aureus osteomyelitis with LY146032 and vancomycin. Eur J Clin Microbiol Infect Dis 1989, 8:562-563.
229. Norden CW, Niederriter K. Treatment of experimental chronic osteomyelitis due to Staphylococcus aureus with LY146032. Infection 1988, 16:27.
230. Forrest GN, Donovan BJ, Lamp KC, Friedrich LV. Clinical experience with daptomycin for the treatment of patients with documented gram-positive septic arthritis. Ann Pharmacother 2008, 42:213-217.
231. Silverman JA, Mortin LI, Vanpraagh AD, Li T, Alder J. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005, 191:2149-2152.
232. Falagas ME, Giannopoulou KP, Ntziora F, Vardakas KZ. Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence. J Antimicrob Chemother 2007, 60:7-19.
233. Mangili A, Bica I, Snydman DR, Hamer DH. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2005, 40:1058-1060.
234. Skiest DJ. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol 2006, 44:655-656.
235. Spanjaard L, Vandenbroucke-Grauls CM. Activity of daptomycin against Listeria monocytogenes isolates from cerebrospinal fluid. Antimicrob Agents Chemother 2008, 52:1850-1851.
236. Cottagnoud P, Pfister M, Acosta F. Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis. Antimicrob Agents Chemother 2004, 48:3928-3933.
237. Gerber P, Stucki A, Acosta F, Cottagnoud M, Cottagnoud P. Daptomycin is more efficacious than vancomycin against a methicillin-susceptible Staphylococcus aureus in experimental meningitis. J Antimicrob Chemother 2006, 57:720-723.
238. Roecker AM, Pope SD. Dalbavancin: a lipoglycopeptide antibacterial for Gram-positive infections. Expert Opin Pharmacother 2008, 9:1745-1754.
239. Anderson VR, Keating GM. Dalbavancin. Drugs 2008, 68:639-648.
240. Dorr MB, Jabes D, Cavaleri M. Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide. J Antimicrob Chemother 2005, 55(suppl 2):ii25-ii30.
241. Jones RN, Stilwell MG, Sader HS, Fritsche TR, Goldstein BP. Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004). Diagn Microbiol Infect Dis 2006, 54:149-153.
242. Raad I, Darouiche R, Vazquez J. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis 2005, 40:374-380.
243. Jauregui LE, Babazadeh S, Seltzer E. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005, 41:1407-1415.
244. Seltzer E, Dorr MB, Goldstein BP, Perry M, Dowell JA, Henkel T. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis 2003, 37:1298-1303.
245. Nannini EC, Stryjewski ME. A new lipoglycopeptide: telavancin. Expert Opin Pharmacother 2008, 9:2197-2207.
246. Leonard SN, Rybak MJ. Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections. Pharmacotherapy 2008, 28:458-468.
247. Barrett JF. Recent developments in glycopeptide antibacterials. Curr Opin Investig Drugs 2005, 6:781-790.
248. Stryjewski ME, O'Riordan WD, Lau WK. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis 2005, 40:1601-1607.
249. Stryjewski ME, Chu VH, O'Riordan WD. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother 2006, 50:862-867.
250. Gotfried MH, Shaw JP, Benton BM. Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics. Antimicrob Agents Chemother 2008, 52:92-97.
251. Rubinstein E. Telavancin for the Treatment of Hospital-Acquired Pneumonia in Severely Ill and Older Patients: The ATTAIN Studies 48th ICAAC 2008, Abst K529
252. Allen NE, Nicas TI. Mechanism of action of oritavancin and related glycopeptide antibiotics. FEMS Microbiol Rev 2003, 26:511-532.
253. Poulakou G, Giamarellou H. Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens. Expert Opin Investig Drugs 2008, 17:225-243.
254. Fetterly GJ, Ong CM, Bhavnani SM. Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose. Antimicrob Agents Chemother 2005, 49:148-152.
255. Van Bambeke F, Carryn S, Seral C. Cellular pharmacokinetics and pharmacodynamics of the glycopeptide antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages. Antimicrob Agents Chemother 2004, 48:2853-2860.
256. Boylan CJ, Campanale K, Iversen PW, Phillips DL, Zeckel ML, Parr TR. Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother 2003, 47:1700-1706.
257. Olson MW, Ruzin A, Feyfant E, Rush TS, O'Connell J, Bradford PA. Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrob Agents Chemother 2006, 50:2156-2166.
258. Bauer G, Berens C, Projan SJ, Hillen W. Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA. J Antimicrob Chemother 2004, 53:592-599.
259. Roveta S, Marchese A, Debbia EA. Tigecycline in vitro activity against gram-negative and gram-positive pathogens collected in Italy. Chemotherapy 2008, 54:43-49.
260. Draghi DC, Tench S, Dowzicky MJ, Sahm DF. Baseline in vitro activity of tigecycline among key bacterial pathogens exhibiting multidrug resistance. Chemotherapy 2008, 54:91-100.
261. Borbone S, Lupo A, Mezzatesta ML, Campanile F, Santagati M, Stefani S. Evaluation of the in vitro activity of tigecycline against multiresistant Gram-positive cocci containing tetracycline resistance determinants. Int J Antimicrob Agents 2008, 31:209-215.
262. Sotto A, Bouziges N, Jourdan N, Richard JL, Lavigne JP. In vitro activity of tigecycline against strains isolated from diabetic foot ulcers. Pathol Biol (Paris) 2007, 55:398-406.
263. Waites KB, Duffy LB, Dowzicky MJ. Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial. Antimicrob Agents Chemother 2006, 50:3479-3484.
264. Sorlozano A, Gutierrez J, Salmeron A. Activity of tigecycline against clinical isolates of Staphylococcus aureus and extended-spectrum beta-lactamase-producing Escherichia coli in Granada, Spain. Int J Antimicrob Agents 2006, 28:532-536.
265. Rose WE, Rybak MJ. Tigecycline: first of a new class of antimicrobial agents. Pharmacotherapy 2006, 26:1099-1110.
266. Gales AC, Jones RN, Andrade SS, Pereira AS, Sader HS. In vitro activity of tigecycline, a new glycylcycline, tested against 1,326 clinical bacterial strains isolated from Latin America. Braz J Infect Dis 2005, 9:348-356.
267. Fritsche TR, Kirby JT, Jones RN. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections. Diagn Microbiol Infect Dis 2004, 49:201-209.
268. Borbone S, Lupo A, Mezzatesta ML, Campanile F, Santagati M, Stefani S. Evaluation of the in vitro activity of tigecycline against multiresistant Gram-positive cocci containing tetracycline resistance determinants. Int J Antimicrob Agents 2008, 31:209-215.
269. Kuti JL, Dowzicky M, Nicolau DP. Pharmacodynamic performance of tigecycline versus common intravenous antibiotics for the empiric treatment of complicated skin and skin structure infections. Surg Infect (Larchmt) 2008, 9:57-66.
270. MacGowan AP. Tigecycline pharmacokinetic/pharmacodynamic update. J Antimicrob Chemother 2008, 62(suppl 1):i11-i16.
271. Hoffmann M, DeMaio W, Jordan RA. Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects. Drug Metab Dispos 2007, 35:1543-1553.
272. Scheetz MH, Reddy P, Nicolau DP. Peritoneal fluid penetration of tigecycline. Ann Pharmacother 2006, 40:2064-2067.
273. Rodvold KA, Gotfried MH, Cwik M, Korth-Bradley JM, Dukart G, Ellis-Grosse EJ. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 2006, 58:1221-1229.
274. Ji AJ, Saunders JP, Wadgaonkar ND. A novel antibiotic bone assay by liquid chromatography/tandem mass spectrometry for quantitation of tigecycline in rat bone. J Pharm Biomed Anal 2007, 44:970-979.
275. Rubino CM, Ma L, Bhavnani SM. Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation. Antimicrob Agents Chemother 2007, 51:4085-4089.
276. Van Wart SA, Cirincione BB, Ludwig EA, Meagher AK, Korth-Bradley JM, Owen JS. Population pharmacokinetics of tigecycline in healthy volunteers. J Clin Pharmacol 2007, 47:727-737.
277. Doan TL, Fung HB, Mehta D, Riska PF. Tigecycline: a glycylcycline antimicrobial agent. Clin Ther 2006, 28:1079-1106.
278. Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis 2005, 52:165-171.
279. Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infect Dis 2005, 41(suppl 5):S333-S340.
280. Breedt J, Teras J, Gardovskis J. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 2005, 49:4658-4666.
281. Sacchidanand S, Penn RL, Embil JM. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase 3, randomized, double-blind trial. Int J Infect Dis 2005, 9:251-261.
282. Passarell JA, Meagher AK, Liolios K. Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections. Antimicrob Agents Chemother 2008, 52:204-210.
283. Wilcox MH. Efficacy of tigecycline in complicated skin and skin structure infections and complicated intra-abdominal infections. J Chemother 2005, 17(suppl 1):23-29.
284. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005, 41(suppl 5):S354-S367.
285. Oliva ME, Rekha A, Yellin A. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections (Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744). BMC Infect Dis 2005, 5:88.
286. Munoz-Price LS, Lolans K, Quinn JP. Four cases of invasive methicillin-resistant Staphylococcus aureus (MRSA) infections treated with tigecycline. Scand J Infect Dis 2006, 38:1081-1084.
287. Cunha BA. Once-daily tigecycline therapy of multidrug-resistant and non-multidrug-resistant gram-negative bacteremias. J Chemother 2007, 19:232-233.
288. Kandemir O, Oztuna V, Colak M, Akdag A, Camdeviren H. Comparison of the efficacy of tigecycline and teicoplanin in an experimental methicillin-resistant Staphylococcus aureus osteomyelitis model. J Chemother 2008, 20:53-57.
289. Yin LY, Lazzarini L, Li F, Stevens CM, Calhoun JH. Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model. J Antimicrob Chemother 2005, 55:995-1002.
290. Zhanel GG, Lam A, Schweizer F. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin. Am J Clin Dermatol 2008, 9:245-254.
291. Pillar CM, Aranza MK, Shah D, Sahm DF. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin. J Antimicrob Chemother 2008, 61:595-602.
292. Anderson SD, Gums JG. Ceftobiprole: an extended-spectrum anti-methicillin-resistant Staphylococcus aureus cephalosporin. Ann Pharmacother 2008, 42:806-816.
293. Leonard SN, Cheung CM, Rybak MJ. Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2008, 52:2974-2976.
294. Fritsche TR, Sader HS, Jones RN. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006). Diagn Microbiol Infect Dis 2008, 61:86-95.
295. Rouse MS, Steckelberg JM, Patel R. In vitro activity of ceftobiprole, daptomycin, linezolid, and vancomycin against methicillin-resistant staphylococci associated with endocarditis and bone and joint infection. Diagn Microbiol Infect Dis 2007, 58:363-365.
296. Murthy B, Schmitt-Hoffmann A. Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity. Clin Pharmacokinet 2008, 47:21-33.
297. Anonymous. Ceftobiprole Medocaril: BAL5788, JNJ 30982081, JNJ30982081, RO 65-5788, RO 655788. Drugs R D 2006, 7:305-311.
298. Noel GJ, Strauss RS, Amsler K, Heep M, Pypstra R, Solomkin JS. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob Agents Chemother 2008, 52:37-44.
299. Laohavaleeson S, Tessier PR, Nicolau DP. Pharmacodynamic characterization of ceftobiprole in experimental pneumonia caused by phenotypically diverse Staphylococcus aureus strains. Antimicrob Agents Chemother 2008, 52:2389-2394.
300. Parish D, Scheinfeld N. Ceftaroline fosamil, a cephalosporin derivative for the potential treatment of MRSA infection. Curr Opin Investig Drugs 2008, 9:201-209.
301. Ge Y, Biek D, Talbot GH, Sahm DF. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob Agents Chemother 2008, 52:3398-3407.
302. Mushtaq S, Warner M, Ge Y, Kaniga K, Livermore DM. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J Antimicrob Chemother 2007, 60:300-311.
303. Talbot GH, Thye D, Das A, Ge Y. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 2007, 51:3612-3616.
304. Jacqueline C, Caillon J, Le Mabecque V. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model. Antimicrob Agents Chemother 2007, 51:3397-3400.
305. Koga T, Masuda N, Kakuta M, Namba E, Sugihara C, Fukuoka T. Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2008, 52:2849-2854.
306. Peppard WJ, Schuenke CD. Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic-resistant staphylococcal infections. Curr Opin Investig Drugs 2008, 9:210-225.
307. Pan A, Lorenzotti S, Zoncada A. Registered and investigational drugs for the treatment of methicillin-resistant Staphylococcus aureus infection. Recent Patents Anti-Infect Drug Disc 2008, 3:10-33.
308. Korbila IP, Falagas ME. Investigational antimicrobial drugs for bloodstream infections. Curr Opin Investig Drugs 2008, 9:871-878.
309. Poulakou G, Giamarellou H. Investigational treatments for postoperative surgical site infections. Expert Opin Investig Drugs 2007, 16:137-155.
310. Schneider P, Hawser S, Islam K. Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria. Bioorg Med Chem Lett 2003, 13:4217-4221.
311. Kohlhoff SA, Sharma R. Iclaprim. Expert Opin Investig Drugs 2007, 16:1441-1448.
312. Laue H, Weiss L, Bernardi A, Hawser S, Lociuro S, Islam K. In vitro activity of the novel diaminopyrimidine, iclaprim, in combination with folate inhibitors and other antimicrobials with different mechanisms of action. J Antimicrob Chemother 2007, 60:1391-1394.
313. John JF. Drug evaluation: tefibazumab-a monoclonal antibody against staphylococcal infection. Curr Opin Mol Ther 2006, 8:455-460.
314. Hetherington S, Texter M, Wenzel E. Phase I dose escalation study to evaluate the safety and pharmacokinetic profile of tefibazumab in subjects with end-stage renal disease requiring hemodialysis. Antimicrob Agents Chemother 2006, 50:3499-3500.
315. Weems JJ, Steinberg JP, Filler S. Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2006, 50:2751-2755.